Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

15 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Colorectal Cancer NCT00077233 Response - CALGB: 80203 Solid Tumor Evaluation Form - 2101473v3.0 - CALGB: 80203 Solid Tumor Evaluation Form

- 09/01/15 - 1 modulo, 1 ItemGroup, 21 elementi, 1 linguaggio
ItemGroup: CCRR MODULE
CALGB: 80203 Solid Tumor Evaluation Form Fluorouracil and Leucovorin Plus Either Irinotecan or Oxaliplatin With or Without Cetuximab in Treating Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BB6E5D42-FA40-4373-E034-0003BA12F5E7

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Response Assessment

- 20/08/19 - 1 modulo, 4 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Administrative documentation, TNM clinical staging, Rectal Carcinoma, Pathological staging, Rectal Carcinoma, Sphincter, Preservation technique
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Adenocarcinoma of the Gastroesophageal Junction NCT01196390 Treatment - RTOG 1010 Post Treatment Response Form (F2) - 3180385v1.0 - RTOG 1010 Post Treatment Response Form (F2)

- 17/09/21 - 1 modulo, 3 itemgroups, 20 elementi, 1 linguaggio
Itemgroups: Header Module, Unnamed 1, Footer Module
RTOG 1010 Post Treatment Response Form (F2) Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99087049-39B3-FC29-E040-BB89AD43284B

Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for Supplemental Form - 2075318v3.0 - E6201 Cover Page for Supplemental Form

- 09/01/15 - 1 modulo, 4 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Header, On Treatment, Off Treatment, CCRR MODULE
E6201 Cover Page for Supplemental Form A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1B0ADEE-BA19-4B20-E034-0003BA12F5E7

Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for Adverse Event Form - 2075284v3.0 - E6201 Cover Page for Adverse Event Form

- 09/01/15 - 1 modulo, 4 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Header, On Treatment, Off Treatment, CCRR MODULE
E6201 Cover Page for Adverse Event Form A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1B0ABAE-0BB9-4B1E-E034-0003BA12F5E7

Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for RECIST Forms - 2075205v3.0 - E6201 Cover Page for RECIST Forms

- 09/01/15 - 1 modulo, 4 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Header, On Treatment, Off Treatment, CCRR MODULE
E6201 Cover Page for RECIST Forms A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1B164EC-ED7F-4A7F-E034-0003BA12F5E7

Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for Hematology/Chemistry Forms - 2075247v3.0 - E6201 Cover Page for Hematology/Chemistry Forms

- 09/01/15 - 1 modulo, 4 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Header, On Treatment, Off Treatment, CCRR MODULE
E6201 Cover Page for Hematology/Chemistry Forms A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1B0A8C1-ED1A-4B19-E034-0003BA12F5E7

CALGB: 80405 FOLLOW-UP AND RESPONSE FORM NCT00265850

- 08/06/15 - 1 modulo, 5 itemgroups, 29 elementi, 1 linguaggio
Itemgroups: Header, Patient demographics, Patient status assessment, RESPONSE DATA, NEW PRIMARY DATA
CALGB: 80405 FOLLOW-UP AND RESPONSE FORM NCT00265850 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F39BEECE-F2C5-5BE1-E034-0003BA3F9857

CALGB: SOLID TUMOR EVALUATION FORM [80303] NCT00088894

- 21/06/15 - 1 modulo, 5 itemgroups, 20 elementi, 1 linguaggio
Itemgroups: Header, Patient demographics, TARGET LESION(S), NON-TARGET LESION(S), Footer module
CALGB: SOLID TUMOR EVALUATION FORM [80303] NCT00088894 Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D6012DD9-1E79-035F-E034-0003BA12F5E7

S0502 Positron Emission Tomography (PET) Assessment Form NCT00324987

- 09/06/15 - 1 modulo, 3 itemgroups, 22 elementi, 1 linguaggio
Itemgroups: Header, Positron Emission Tomography (PET) Assessment, Comments
S0502 Positron Emission Tomography (PET) Assessment Form NCT00324987 S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBE8452-90FE-734C-E034-0003BA3F9857

Nontarget Lesions Supplemental Form NCT00058149

- 03/06/15 - 1 modulo, 4 itemgroups, 20 elementi, 1 linguaggio
Itemgroups: ECOG clinical trial administrative data, NONTARGET LESIONS:, Comments, CCRR MODULE
Nontarget Lesions Supplemental Form NCT00058149 A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A65D5AC6-6244-4284-E034-0003BA0B1A09

Nontarget Lesions Supplemental Form NCT00057876

- 03/06/15 - 1 modulo, 4 itemgroups, 20 elementi, 1 linguaggio
Itemgroups: ECOG clinical trial administrative data, NONTARGET LESIONS:, Comments, CCRR MODULE
Nontarget Lesions Supplemental Form NCT00057876 Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A6238F51-F0B5-3C1D-E034-0003BA0B1A09

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial